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Abstract
We report a four-component partial least squares discriminant analysis (PLS) model for the prediction of blood–brain barrier (BBB)
permeation using descriptors derived from 3D molecular fields. The 3D fields were transformed by VolSurf into suitable 1D descriptors,
which were correlated to the ratio of blood–brain partitioning measured at steady state in rats (log Cbrain/Cblood). The model so obtained sheds
light on molecular properties influencing BBB permeation. It can also be used in the virtual screening of new chemicals. D 2002 Elsevier
Science B.V. All rights reserved.
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1. Introduction
The blood–brain barrier (BBB) has peculiar character-
istics among the various physiological barriers. Diffusion of
drugs across this endothelium separating the blood from the
central nervous system (CNS) is in fact more restrictive than
elsewhere. Endothelial cells provide a crucial interface
between blood and tissues. The free diffusion of chemicals
across endothelia is prevented by endothelial tight junctions,
the permeability of which varies considerably depending on
tissue and conditions. In peripheral tissues (intestine, kid-
ney, salivary gland), these cell barriers have fenestrations
enabling relatively facile exchange of water and solutes. In
contrast, the endothelial barrier separating the blood from
the CNS is characterized by tight junctions of severely
limited permeability (excluding molecules with a diameter
larger than 20 A˚), no fenestrae and an attenuated pinocytosis
[1,2].
As a common feature, both peripheral and blood–brain
endothelial cells have significant metabolic activity [3].
Moreover, and in contrast to what was for long the common
view, the special features of the BBB seem to be subject to
endogenous regulation [1].
Thus, the BBB is far from being a simple barrier.
Understanding its structure and functions, as well as the
physicochemical and biological factors that control solute
transfer, is a problem of great currency in pharmaceutical
research. This is true not only for the design and develop-
ment of CNS-active agents, but also for drugs that must
be forbidden entry into the CNS to avoid unwanted side-
effects, as exemplified by anti-histamines [4] and h-
blockers [5]. Hence, in drug discovery, early assessment
of BBB permeation is of great importance, and in vitro
and in vivo techniques have been devised for this purpose
[6].
Besides these experimental techniques, computational
approaches have also been developed to predict the BBB
permeation of new chemicals since the experimental determi-
nation of BBB penetration is laborious, expensive, time-con-
suming and requires a sufficient quantity of pure compound,
often in radiolabeled form, to obtain good experimental data.
Therefore, a fast and reliable computational method to predict
BBB permeation at an early stage of discovery could
help decrease the attrition curve since it would allow the
virtual screening of many compounds prior to synthesis.
Over the years, various authors have attempted to predict
BBB transport using lipophilicity (log P) [7–9], solvatochro-
mic parameters [10], H-bonding capacity [11–14], topolog-
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ical indices [15], polar surface area (PSA) [16–19] and
Molsurf descriptors [20].
Recently, a new method named VolSurf has been devel-
oped by Cruciani et al. [21]. This method is able to convert
3D fields into new descriptors well suited for structure–
pharmacokinetic relationships [22,23] and have proven its
efficacy, simplicity of use and chemical interpretability (see
Ref. [21] for a detailed description of the method). A
previous semiquantitative model was able to classify cor-
rectly more than 90% of BBB+ and BBB permeation data
[23]. In the present work, a quantitative model is presented,
which was derived from log(Cbrain/Cblood) steady-state (log
BB) values of 83 compounds measured in rats.
2. Experimental procedures
2.1. Overview
The overall procedure consisted in the following four
major steps:
1. Compilation of a homogenous set of literature BBB
data for 83 compounds.
2. Calculation of their 3D structure.
3. Computation of their molecular interaction fields
(MIFs) using GRID probes.
4. Generation of the VolSurf descriptors.
Table 1
Experimental and calculated log BB values for the compounds included in this study
Compound Name log BBexp log BBcalc Reference Compound Name log BBexp log BBcalc Reference
1 cimetidine  1.42  1.188 [14] 44 valproic-acid  0.22 0.598 [25]
2 clonidine 0.11 0.462 [14] 45 chlorambucil  1.70 outlier [15]
3  0.04  0.563 [14] 46  1.3  1.162 [11]
4 imipramine 0.83 0.923 [14] 47  1.4  0.918 [11]
5 mepyramine 0.49 0.521 [14] 48  0.43  0.397 [15]
6 ranitidine  1.23  0.605 [14] 49 0.25 0.193 [15]
7 tiotidine  0.82  1.144 [14] 50  0.3  0.244 [11]
8 icotidine  2  1.222 [14] 51  0.06 0.468 [11]
9 SKF-93619  1.3  0.410 [14] 52  0.42  1.435 [11]
10 lupitidine  1.06  1.232 [14] 53  0.16 0.222 [15]
11  1.17  0.707 [14] 54 thioridazine 0.24 0.781 [25]
12  2.15 outlier [14] 55 chlorpromazine 1.06 0.422 [25]
13  0.67  0.718 [14] 56 desipramine 1.2 0.420 [25]
14  0.66  0.680 [14] 57 alprazolam 0.044  0.375 [25]
15  0.12  0.603 [14] 58 codeine 0.55 0.543 [25]
16  0.18  0.282 [14] 59 didanosine  1.301  1.296 [15]
17  1.15  0.669 [14] 60 oxazepam 0.61  0.659 [25]
18  1.57  1.313 [14] 61 verapamil  0.7  0.960 [25]
19  1.54  1.252 [14] 62 trifluopromazine 1.44 outlier [25]
20  1.12  0.739 [14] 63 theophylline  0.29  0.955 [25]
21  0.73  0.763 [14] 64 pentobarbital 0.12  0.535 [25]
22  0.27  0.231 [14] 65 hyroxyzine 0.39  0.881 [25]
23  0.28  0.492 [14] 66 midazolam 0.36 0.412 [25]
24  0.46 0.158 [14] 67 promazine 1.23 0.651 [25]
25  0.24 0.111 [14] 68 physostigmine 0.079 0.380 [15]
26  0.02  0.037 [14] 69 nevirapine 0 0.083 [15]
27 0.69 0.322 [14] 70 mianserin 0.99 0.906 [17]
28 0.44  0.222 [14] 71 Org-4428 0.82 1.010 [17]
29 zolantidine 0.14  0.277 [14] 72 Org-5222 1.03 0.614 [17]
30 0.22 0.186 [14] 73 Org-12962 1.64 outlier [17]
31 amitriptyline 0.89 0.742 [10] 74 Org-32104 0.52 0.066 [17]
32 carbamazepine 0 0.313 [15] 75 Org-30526 0.39 0.036 [17]
33  0.34  0.153 [15] 76 mirtazapine 0.53 0.506 [17]
34 L-663581  0.3  0.089 [24] 77 tibolone 0.4 0.911 [17]
35 M1L-663581  1.34  0.882 [24] 78 domperidone  0.78  0.586 [17]
36 M2L-663581  1.82  1.568 [24] 79 Org-34167 0 0.240 [17]
37 antipyrine  0.097 0.495 [25] 80 risperidone  0.02  0.479 [17]
38 caffeine  0.055  0.870 [25] 81 9-OH-risperidone  0.67  0.909 [17]
39 ibuprofen  0.18 0.220 [25] 82 BCNU  0.52  0.191 [15]
40 indomethacin  1.26  1.146 [25] 83 phenserine 1 0.679 [15]
41 salicylic-acid  1.1  0.657 [25]
42 temelastine  1.88  1.059 [26]
43 aspirin  0.5  0.516 [25]
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5. Statistical analysis using principal component
analysis (PCA) and partial least squares discrim-
inant analysis (PLS).
Steps 3–5 were performed automatically by the VolSurf
program.
2.2. Dataset
Log BB data for 83 radiolabeled compounds were
compiled from the literature (Table 1) [10,11,14,15,17,24–
26]. These values were blood/brain concentration ratios
obtained in the rat at steady state:
logBB ¼ logðCbrain=CbloodÞ ð1Þ
The values within this dataset ranged from  2.16 to 1.64.
A basic assumption of the study was that BBB permeation
was purely passive.
2.3. Modelling of 3D molecular structures
The 3D structure of the selected compounds (Fig. 1) were
drawn starting from the Corina-built structures, and energy-
optimized using the MMFF94s force field including
MMFF94 partial atomic charges as implemented in Sybyl
6.4 [27]. Minimization was performed in vacuo (e = 1) using
BFGS and continued until the root-mean-square energy
gradient was lower than 0.001 kcal/mol. All molecules were
built in their neutral forms. Because it is impossible to model
mixtures of stereoisomers in 3D and since VolSurf descrip-
tors are achiral, only one of stereoisomer was modelled.
2.4. Calculation of VolSurf descriptors and statistical
analysis
The MIFs were calculated using the water, DRY, and
carbonyl probes available in the GRID program [28]. The
GRID forcefield is indeed well suited to characterize puta-
tive polar and hydrophobic interaction sites around target
molecules. The water probe was used to simulate hydra-
tion–dehydration processes, the hydrophobic (DRY) probe
was used to simulate drug–membrane hydrophobic inter-
actions, and the carbonyl probe was used to simulate drug–
membrane H-bonding interactions [23]. Descriptors were
then automatically generated by VolSurf. These descriptors
refer to molecular size and shape, to size and shape of
hydrophilic and hydrophobic regions, and to the balance
between them. Hydrogen bonding, amphiphilic moments
Fig. 1. Chemical structure of the compounds in the dataset.
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and critical packing parameters are other useful descriptors
(for a more detailed description, see Ref. [21]).
PCA and PLS analyses were produced with the VolSurf
program version 2.0.6. The number of significant latent
variables and the quality of the models were determined
using a leave-one-out cross-validation procedure (LOO-cv).
In such a procedure, each compound is removed once from
the dataset, and the remaining compounds are used to
develop a new model, with which the left-out compound
is then predicted.
3. Results and discussion
3.1. Preliminary BBB permeation model
In a first investigation, VolSurf molecular descriptors
were computed for the 83 compounds included within the
dataset using the water, DRY and carbonyl probes, yielding
72 descriptors. This led for the 83 compounds to a four-
component PLS model (Table 2; model 1), which explained
about 65% of the total variance of the matrix. The predictive
ability of the model was assessed by means of cross-
validation (leave-one-out). A detailed inspection of the
predicted residual plots showed several strong outliers (eight
compounds). Removing compounds 12 and 45 (the same
outliers as in previous studies [10,15,26] and compounds 62
and 73 resulted for the 79 remaining compounds in an
improved four-component PLS model (Table 2, model 1b).
Compounds 62 and 73 were remove since a careful inspec-
tion of the MIFs obtained with the DRY probe showed that
the trifluoromethyl group was not well described by this
probe.
3.2. Final BBB permeation model and its interpretation
A systematic examination showed that it was possible to
use only the three lowest energy levels calculated with the
water and DRY probes, and canceling the carbonyl probe.
Indeed, the correlation matrix revealed that several descrip-
tors generated from the carbonyl probe correlated with those
obtained with the water probe. This observation is not too
surprising since the water probe already accounts for the
polarity of the studied compounds.
As a result of these restrictions, the independent variables
were reduced to 31 descriptors. The statistics of this new
four-component PLS model (Table 2, model 2; Fig. 2) were
similar to those of model 1b. The coefficient plot of this
final model (Fig. 3) shows the contribution of the 31
VolSurf descriptors. The vertical bars represent the contri-
Fig. 1 (continued).
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bution of each single descriptor, a short bar denoting a
minor contribution and a long bar a major one. The last bar
on the right represents the dependent variable, i.e. log BB.
The following conclusions can be drawn from this plot:
. Descriptors of polarity such as hydrophilic regions
(W1–W3) and capacity factors (CW1–CW3) are inversely
correlated with BBB permeability. Their negative coeffi-
cients are in line with the well-known fact that highly polar
compounds have a very low BBB permeation.
. The descriptors of hydrophobic interactions (D1–D3)
are directly correlated with BBB permeation, although their
positive contribution appears somewhat smaller than the
negative contribution of the polar descriptors. These pos-
itive contributions are in accordance with the fact that
lipophilic compounds penetrate relatively easily into the
brain.
. The size and shape descriptors have no marked impact
on BBB permeation except for rugosity, which correlates
positively with BBB permeation, and globularity, which
correlates negatively. Rugosity is defined as the ratio of total
volume (Vtot) over total surface (Stot), and it is smaller the
more the object differs from a sphere. Globularity is defined
as the ratio between Stot and the surface of a sphere of
equivalent volume (Vtot), and it is larger the more the object
differs from a sphere. In other words, both descriptors
indicate that compounds having a high rugosity and a low
globularity will have a spherical shape and will be better at
crossing the BBB.
Table 2
Statistical properties of the models
Model Training set N descriptors r2 (four LVs) q2
1 83 compounds 72 0.68 0.50
1b 79 compounds 72 0.78 0.65
2 79 compounds 31 0.76 0.65
Fig. 2. Relationship between experimental and calculated BBB permeation
using the four-component PLS model (Table 2, model 2).
Fig. 1 (continued).
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3.3. Application to two compounds in the dataset
Here, we discuss in some detail two compounds to
exemplify the interpretative value of the VolSurf model.
These compounds are characterized by different BBB per-
meation properties: 70 easily crosses the BBB while 59 does
not.
The scaled values of the descriptors (Fig. 4) show several
trends:
. The hydrophilic descriptors (W1–W3, CW1–
CW3) of 70 are lower than those of 59.
. The hydrophobic descriptors (D1–D3) of 70 are
larger than those of 59.
. Relative to 59, the rugosity of 70 is higher whereas
the globularity is lower.
A visual comparison of the MIFs calculated around
compounds 59 and 70 with the water and DRY probes also
shows several differences (Fig. 5). The dark gray zones
represent the hydrophilic regions in Fig. 5 left, and the
hydrophobic regions in Fig. 5 right. As can be seen, the
hydrophilic regions generated around 59 are larger than
those around 70 while the reverse holds for the hydrophobic
regions. These results are in agreement with our above
analysis of the PLS coefficient plot (Fig. 3), namely that
the size of the hydrophilic regions is inversely correlated
with BBB permeation whereas the opposite is true for the
hydrophobic regions. Furthermore, 70 indeed has a more
spherical shape than 59.
3.4. Interest of the model in virtual screening of BBB
permeation
The four-component PLS model can also be used to
perform a semiquantitative classification of compounds
based on their permeation or nonpermeation of the BBB.
Compounds having a log BB value > 0 were classified has
brain penetrators (BBB+) while those with a log BB value
< 0 were considered as not reaching the brain in sufficient
concentrations (BBB ). It is important to note that this
cutoff is arbitrary and would have to be defined with a
specific pharmacology in mind. Indeed, the cutoff value will
depend on which are more damaging to the classification,
false positives or false negatives. Eighty-five percent of the
BBB compounds and 79% of BBB+ compounds
were correctly classified with a cutoff of 0. If more restric-
tive cutoffs are chosen to define BBB compounds (log
BB< 0.5) and BBB+ compounds (log BB>0.5), the mo-
del correctly assign more than 90% of the BBB com-
pounds and 65% of the BBB+ compounds.
4. Conclusion
The model obtained in this study for the prediction of
BBB permeation is relevant from a physiological point of
view and is also in agreement with insights from other BBB
permeation models. We show that VolSurf descriptors
describing hydrophilic and hydrophobic properties are well
Fig. 3. PLS coefficient plot for the final model (Table 2, model 2) for the
correlation of VolSurf descriptors with BBB permeation.
Fig. 4. Thirty-one VolSurf scaled descriptors calculated for compounds 59
(didanosine, upper part) and 70 (mianserine, lower part).
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suited to derive a PLS model able to discriminate good and
poor BBB penetrators. Finally, we believe that a more
robust model to predict log BB values could be obtained
from BBB data measured by a single experimental protocol
and for compounds permeating by a purely passive mech-
anism.
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